JAGX Insider Trading Activity and SEC Form 4 Filings
JAGX insider trading summary
No open-market insider purchases or sales of Jaguar Health, Inc. (JAGX) have been reported on SEC Form 4 in the past 12 months.
Latest JAGX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 31, 2022 | Jonathan S. Wolin | Chief of Staff, CCO & GC | Buy | $10 (317 @ $0.03) |
| Sep 13, 2021 | Lisa A Conte | CEO and President | Buy | $20K (7,968 @ $2.51) |
| Sep 13, 2021 | Carol R. Lizak | Chief Financial Officer | Buy | $20K (7,968 @ $2.51) |
| Jun 4, 2021 | James J Bochnowski | Director | Sell | $264 (152 @ $1.74) |
| Jun 3, 2021 | James J Bochnowski | Director | Sell | $511 (292 @ $1.75) |
| Jul 23, 2019 | James J Bochnowski | Director | Buy | $361K (180,582 @ $2.00) |
| Jul 23, 2019 | Jonathan B. Siegel | Director | Buy | $25K (12,705 @ $2.00) |
| Oct 4, 2018 | Jonathan B. Siegel | Director | Buy | $15K (25,000 @ $0.60) |
| Sep 25, 2018 | Nantucket Investments Ltd | 10% Owner | Sell | $596K (325,615 @ $1.83) |
| Sep 25, 2018 | Burford Capital Ltd | 10% Owner | Sell | $596K (325,615 @ $1.83) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.